AVR's valve is a bioprosthetic valve. that's just a fancy name for a valve made from organic material.
your valve is not a cow's valve, rather made from bovine. most bio valves are made from porcine or bovine. there are no valves made from human material that I am aware of and I am not aware if there is any possibility to harvest from organ donors.
AVR's difference is in the ADAPT technology and one piece construction.
so if patients would pick bio as you've suggested, then AVR would be the valve of choice.
what's even better is the upgrade to TAVR application of the valve.
SAVR or TAVR, our valve, I believe will absolutely be the valve of choice.
with regards to anticoagulants, despite the research around what's normal to prescribe or not prescribe drugs like Warfarin, it will still need to be a patient by patient decision made by the cardiologist as patients may have different needs for it.
With the "works better and lasts longer" that includes much better leaflet action and blood flow, therefore we would expect this to help reduce the need for anticoagulants and be likely suited for patients of all ages. TAVR in TAVR could provide a lifetime solution for almost all patients and far less invasive.
INR levels being stable or not varies patient to patient. I've had to attend some patients residence to take INR levels every day for the rest of their lives and others as long as once a month. There are so many factors involved including overall health, specific conditions, medications, food and activity level of each patient that can make a difference.
IMO, AVR is a great product that we hope to see in the market. DYOR
Also, good luck with your health, all the best!
- Forums
- ASX - By Stock
- AVR
- AGM questions to be submitted to the CEO
AGM questions to be submitted to the CEO, page-26
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$9.90 |
Change
-0.100(1.00%) |
Mkt cap ! $208.2M |
Open | High | Low | Value | Volume |
$10.00 | $10.00 | $9.65 | $46.27K | 4.713K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4 | $9.79 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$9.90 | 133 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4 | 9.790 |
3 | 1112 | 9.780 |
1 | 49 | 9.770 |
1 | 180 | 9.750 |
1 | 150 | 9.730 |
Price($) | Vol. | No. |
---|---|---|
9.900 | 133 | 1 |
9.910 | 567 | 2 |
9.990 | 265 | 2 |
10.000 | 794 | 2 |
10.500 | 10005 | 2 |
Last trade - 13.03pm 12/11/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online